Hybrid Adenoviral Vectors

Stephen J. Murphy, Richard Geoffrey Vile

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The characterization of disease at the genetic level facilitates potential genotypic and/or phenotypic correction by gene therapy. Although the concept of gene therapy has been extensively established over the past two decades, the development of effective clinical protocols to facilitate efficacious reversal of disease has proven highly problematic. The development of an effective gene delivery system to the site of therapeutic significance has proven to be the major hurdle to the advancement of gene therapies. Many questions currently remain unanswered and these raise major debates over the best vector systems to treat a specific clinical disorder, and at a more fundamental level the choice of gene to be applied. The ultimate goal of a gene therapy protocol is the efficient targeted delivery of a therapeutic transgene, whose expression can be sufficiently regulated, in a defective tissue. Vector delivery would ideally involve a single, lifetime treatment by a simple, non-invasive, and safe protocol, which can be incorporated into clinical practice. The vast array of clinical diseases, for which gene therapy presents clinical promise, demands a multitude of different requirements for a vector system to meet.

Original languageEnglish (US)
Title of host publicationAdenoviral Vectors for Gene Therapy: Second Edition
PublisherElsevier Inc.
Pages451-493
Number of pages43
ISBN (Print)9780128002766
DOIs
StatePublished - Apr 6 2016

Fingerprint

Gene therapy
Genetic Therapy
Genes
Gene Transfer Techniques
Inborn Genetic Diseases
Clinical Protocols
Transgenes
Therapeutics
Tissue

Keywords

  • Adeno-associated virus
  • Adenovirus
  • Cassettes
  • Herpes simplex
  • Retrovirus
  • Targeting strategies
  • Transgene expression
  • Viral vectors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Murphy, S. J., & Vile, R. G. (2016). Hybrid Adenoviral Vectors. In Adenoviral Vectors for Gene Therapy: Second Edition (pp. 451-493). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-800276-6.00018-8

Hybrid Adenoviral Vectors. / Murphy, Stephen J.; Vile, Richard Geoffrey.

Adenoviral Vectors for Gene Therapy: Second Edition. Elsevier Inc., 2016. p. 451-493.

Research output: Chapter in Book/Report/Conference proceedingChapter

Murphy, SJ & Vile, RG 2016, Hybrid Adenoviral Vectors. in Adenoviral Vectors for Gene Therapy: Second Edition. Elsevier Inc., pp. 451-493. https://doi.org/10.1016/B978-0-12-800276-6.00018-8
Murphy SJ, Vile RG. Hybrid Adenoviral Vectors. In Adenoviral Vectors for Gene Therapy: Second Edition. Elsevier Inc. 2016. p. 451-493 https://doi.org/10.1016/B978-0-12-800276-6.00018-8
Murphy, Stephen J. ; Vile, Richard Geoffrey. / Hybrid Adenoviral Vectors. Adenoviral Vectors for Gene Therapy: Second Edition. Elsevier Inc., 2016. pp. 451-493
@inbook{ccd4a0541c3e41cc817c2863e4342ca0,
title = "Hybrid Adenoviral Vectors",
abstract = "The characterization of disease at the genetic level facilitates potential genotypic and/or phenotypic correction by gene therapy. Although the concept of gene therapy has been extensively established over the past two decades, the development of effective clinical protocols to facilitate efficacious reversal of disease has proven highly problematic. The development of an effective gene delivery system to the site of therapeutic significance has proven to be the major hurdle to the advancement of gene therapies. Many questions currently remain unanswered and these raise major debates over the best vector systems to treat a specific clinical disorder, and at a more fundamental level the choice of gene to be applied. The ultimate goal of a gene therapy protocol is the efficient targeted delivery of a therapeutic transgene, whose expression can be sufficiently regulated, in a defective tissue. Vector delivery would ideally involve a single, lifetime treatment by a simple, non-invasive, and safe protocol, which can be incorporated into clinical practice. The vast array of clinical diseases, for which gene therapy presents clinical promise, demands a multitude of different requirements for a vector system to meet.",
keywords = "Adeno-associated virus, Adenovirus, Cassettes, Herpes simplex, Retrovirus, Targeting strategies, Transgene expression, Viral vectors",
author = "Murphy, {Stephen J.} and Vile, {Richard Geoffrey}",
year = "2016",
month = "4",
day = "6",
doi = "10.1016/B978-0-12-800276-6.00018-8",
language = "English (US)",
isbn = "9780128002766",
pages = "451--493",
booktitle = "Adenoviral Vectors for Gene Therapy: Second Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Hybrid Adenoviral Vectors

AU - Murphy, Stephen J.

AU - Vile, Richard Geoffrey

PY - 2016/4/6

Y1 - 2016/4/6

N2 - The characterization of disease at the genetic level facilitates potential genotypic and/or phenotypic correction by gene therapy. Although the concept of gene therapy has been extensively established over the past two decades, the development of effective clinical protocols to facilitate efficacious reversal of disease has proven highly problematic. The development of an effective gene delivery system to the site of therapeutic significance has proven to be the major hurdle to the advancement of gene therapies. Many questions currently remain unanswered and these raise major debates over the best vector systems to treat a specific clinical disorder, and at a more fundamental level the choice of gene to be applied. The ultimate goal of a gene therapy protocol is the efficient targeted delivery of a therapeutic transgene, whose expression can be sufficiently regulated, in a defective tissue. Vector delivery would ideally involve a single, lifetime treatment by a simple, non-invasive, and safe protocol, which can be incorporated into clinical practice. The vast array of clinical diseases, for which gene therapy presents clinical promise, demands a multitude of different requirements for a vector system to meet.

AB - The characterization of disease at the genetic level facilitates potential genotypic and/or phenotypic correction by gene therapy. Although the concept of gene therapy has been extensively established over the past two decades, the development of effective clinical protocols to facilitate efficacious reversal of disease has proven highly problematic. The development of an effective gene delivery system to the site of therapeutic significance has proven to be the major hurdle to the advancement of gene therapies. Many questions currently remain unanswered and these raise major debates over the best vector systems to treat a specific clinical disorder, and at a more fundamental level the choice of gene to be applied. The ultimate goal of a gene therapy protocol is the efficient targeted delivery of a therapeutic transgene, whose expression can be sufficiently regulated, in a defective tissue. Vector delivery would ideally involve a single, lifetime treatment by a simple, non-invasive, and safe protocol, which can be incorporated into clinical practice. The vast array of clinical diseases, for which gene therapy presents clinical promise, demands a multitude of different requirements for a vector system to meet.

KW - Adeno-associated virus

KW - Adenovirus

KW - Cassettes

KW - Herpes simplex

KW - Retrovirus

KW - Targeting strategies

KW - Transgene expression

KW - Viral vectors

UR - http://www.scopus.com/inward/record.url?scp=84969597445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969597445&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-800276-6.00018-8

DO - 10.1016/B978-0-12-800276-6.00018-8

M3 - Chapter

SN - 9780128002766

SP - 451

EP - 493

BT - Adenoviral Vectors for Gene Therapy: Second Edition

PB - Elsevier Inc.

ER -